Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06716645 · ClinicalTrials.gov registry record · Phase 4
A Clinical Evidence Study Evaluating Quality of Life Parameters Following Treatment With Robitussin
A Phase 4 study of Cough and Common Cold, sponsored by HALEON.
- Completed
- Registry status
- Phase 4
- Development phase
- 244
- Enrollment target
- 1
- Study location
NCT06716645: Completed Phase 4 study of Cough and Common Cold, sponsored by HALEON.
NCT06716645 is a Phase 4 study of Cough and Common Cold that has completed, run by HALEON. The registered enrollment target is 244 participants, above the 202-participant average among 12 other Cough trials with a reported enrollment target (21% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06716645, a Phase 4 study of Cough and Common Cold, has completed, sponsored by HALEON.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 244 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this Real-World Evidence study is to generate real world data from participants with cough associated with the common cold, evaluating the effects in two arms with commercially available cough syrups on health-related quality of life (QoL). Arm 1 includes one cough syrup (which can be used day or night) and Arm 2 includes the daytime cough syrup and a nighttime cough syrup.
Primary Outcome
The WURSS was an evaluative illness-specific quality of life instrument, designed to assess the negative impact of acute upper respiratory infection, presumed viral (the common cold). WURSS-21 was the short version of this validated survey. Participants rated their cold symptoms (10 questions) and Quality of Life (QoL) related 9 questions using WURSS-21. The responses were evaluated on a scale ranging from 0 to 7, where 0=Do not have symptoms/Not at all and 7=Severe symptoms/Severely. Thus, the
Conditions Studied
Interventions
- DRUG Robitussin Maximum Strength Cough and Chest Congestion DM
- DRUG Robitussin Maximum Strength Nighttime Cough DM
Study Locations (1)
New York
- Lindus Health Limited - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 244 participants |
| Start Date | 2024-12-04 |
| Est. Completion | 2025-02-14 |
| Phase | Phase 4 |
What the finished NCT06716645 record still lists
NCT06716645 is an interventional study that assigns participants to a tested intervention. The registered 244 participants enrollment target is mid-sized for trials with a published cap, above the 202-participant average among 12 other Cough trials with a reported enrollment target (21% higher).
The record links to 2 conditions, with Cough appearing as the primary indexed condition, and to 2 interventions - of which Robitussin Maximum Strength Cough and Chest Congestion DM is the first listed.
NCT06716645 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06716645 about?
NCT06716645 is a clinical study titled "A Clinical Evidence Study Evaluating Quality of Life Parameters Following Treatment With Robitussin". The purpose of this Real-World Evidence study is to generate real world data from participants with cough associated with the common cold, evaluating the effects in two arms with commercially available cough syrups on health-related quality of life (QoL). Arm 1 includes one cough syrup (which can be...
What is the current status of trial NCT06716645?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 244 participants. The study started on 2024-12-04. Estimated completion is 2025-02-14.
What conditions does trial NCT06716645 study?
This clinical trial studies the following conditions: Cough, Common Cold.
What interventions are being tested in trial NCT06716645?
The interventions under investigation include: Robitussin Maximum Strength Cough and Chest Congestion DM (DRUG), Robitussin Maximum Strength Nighttime Cough DM (DRUG).
Who is sponsoring clinical trial NCT06716645?
This trial is sponsored by HALEON, which has 34 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06716645 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cough
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06716645's enrollment target sits among peer trials
244 3rd of 12 higher than 10 of 12 other Cough trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cough trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Mechanism Versus PPI Trial
RECRUITING · Phase 4
-
A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
RECRUITING · Phase 3
-
Office-Based Superior Laryngeal Nerve Block for Treatment of Neurogenic Cough
RECRUITING
-
Stimulation of the Larynx to Treat Unexplained Chronic Cough
RECRUITING · NA
-
Work of Breathing Assessment in Triage Scale
ACTIVE NOT RECRUITING
-
A 52-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02227251 · 244 participants · Phase 2
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
- NCT04317534 · 244 participants · Phase 2
Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
- NCT04683250 · 244 participants · Phase 1
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities
- NCT04686305 · 244 participants · Phase 1
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI